Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
about
Modulation in vitro of human natural cytotoxicity, lymphocyte proliferative response to mitogens and cytokine production by essential fatty acidsCytokine-induced NK-like T cells: from bench to bedside.Immunotherapeutic Intervention against Sarcomas.Lysis of primary hepatic tumours by lymphokine activated killer cellsInfluence of natural and recombinant interleukin 2 on endothelial cell arachidonate metabolism. Induction of de novo synthesis of prostaglandin H synthase.Application of IL-2 and other cytokines in renal cancer.The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression.Anti-tumour efficacy of mouse spleen cells separated with Dolichos biflorus lectin (DBA) in experimental pulmonary metastasis of B16 melanoma cellsGene-expression profiling in vaccine therapy and immunotherapy for cancerHuman lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles.Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2.Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs.Lymphokine-activated-killer-mediated lysis of cells infected with typhus group rickettsiae can be inhibited by OKT3 monoclonal antibodyInterferon response factor 3 is crucial to poly-I:C induced NK cell activity and control of B16 melanoma growth.Enhancing adoptive immunotherapy of cancer.Passive immunotherapeutic strategies for the treatment of malignant gliomas.Is antigen specificity the key to efficient adoptive T-cell therapy?Is adoptive T-cell therapy for solid tumors coming of age?T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients.Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy.Targeting cancer-specific mutations by T cell receptor gene therapy.Adoptive Cellular Therapy (ACT) for Cancer Treatment.The clinical potential of interleukin-2.Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.Activation of lymphocyte anti-tumor responses in man. Towards an understanding of effector cell heterogeneity?Lymphokine-activated killer cells: biology and relevance to disease.Immunomodulating drugs: major advances in research and development.Antitumor properties of mononuclear cells activated by combined treatment with oxidizing mitogens and interleukin-2: basic and clinical studies.Augmentation by tumor necrosis factor alpha of the systemic therapeutic effect of lymphokine-activated killer cells in adoptive immunotherapy of murine tumor.The heterogeneity of target recognition by lymphokine-activated killer precursor cells.The Role of Tumor Microenvironment in Cancer Immunotherapy.Biodistribution of iodine-125 labeled monoclonal antibody/interleukin-2 immunoconjugate in athymic mice bearing human tumor xenografts.Harnessing the immune system in the battle against breast cancer.IL-2 and Beyond in Cancer Immunotherapy.Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.LPS augments adoptive transfer of experimental allergic encephalomyelitis in the Lewis rat.Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?Interleukin-2 in the treatment of malignant melanoma.
P2860
Q28379281-087877A1-27C0-4F80-9BF1-9F23219C2919Q33762499-AE80A7F7-B204-4DD2-8A08-B92C31031B7AQ34196481-83A45CFF-C6F4-4B8E-9924-66C3F604F326Q34527814-49F51F0C-4B90-4937-9043-3AD58E76706BQ35594188-147CA4A4-EC1D-4FE9-9446-0D5C1A49EC30Q35753505-970EFD4A-B63D-4B9A-B446-AF75D62C5A74Q35856332-0E000DC6-62BB-444B-A75D-3994988029A4Q35981853-E0E5E3DE-E072-4A44-8E04-C51C47506C6BQ36138329-C60FAB72-921D-4F63-A108-BA834ECBF24EQ36232048-04767C4A-AD73-40FC-B8D0-3376C93DD240Q36327671-7CBBC5B3-84B6-40A7-87DF-A8AB2E6E3115Q36350050-D7957D05-6A85-48C2-A1A2-999CAF3DD0E1Q36352357-7C0D9FEB-5B06-4F8D-9BA6-2410C3443ECBQ36889622-6E113FE5-9848-45A9-9FCB-70D8743257C2Q37011658-88579300-8F17-4920-9EBD-8F574A9CDFE5Q37657851-A30AC82C-6CBF-41BB-96DF-206924D6923BQ37687429-11BC1D5C-BF94-4850-87F7-03152ACC8343Q37714783-4B060797-1345-4EA1-80D8-4CBF5D3AE3ABQ37861214-A9F562C1-0FBC-438E-B940-97D40EA93A45Q37909004-2025C460-30BC-4778-B533-9085AA892712Q38101679-71068B53-2389-4834-AB76-3BB908349FDAQ38214635-823D40C1-A1E1-4813-A67B-7BBC3A86E3C0Q38366556-9B1FCCB3-6EF5-448C-8E9D-0BC66335C12DQ38848219-860F5258-545E-4B3D-B235-EDDAB376FC94Q39550760-A3B77AC9-4AD1-4693-A8F5-0C75A569635AQ39669347-4E137B64-E34B-42FC-954C-07086D14D623Q40117876-0DB2BBCB-0244-444B-8E97-753C4CFCADD8Q40822463-2A6DDA1A-30CD-47C0-A3BA-8DEC545E5D1BQ40841437-B7138DC7-04AF-4044-BC22-522FF64C785EQ41849898-BCB3B3D8-776A-48D0-AD8C-2C6432257902Q44077891-4C08AB75-0D62-4695-BCB4-5D81CE234164Q45350890-442D2383-EE5A-41D9-A2A4-DF552DE6A07DQ47252754-B8ADA0DB-4501-4D2D-99C6-AD2AD6579CBCQ47618166-613A77A1-812C-425D-9E63-29938717375FQ49884762-FC6527C1-26AD-413D-88E3-506387D9A20FQ50004232-0CB67905-EABD-4B2F-A336-260D2B8D7AAFQ50034069-AA2251B1-6D6B-4CBA-8664-29189A5B0B42Q52068075-300B58CD-483A-4338-81C0-6AD1E5056C38Q53076079-FF79D6DA-4F7D-44F7-B97F-54FE221A0A71Q53668254-FA0C8052-577A-429F-9CB3-7E1FC47DF298
P2860
Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
Successful immunotherapy of na ...... ted in vitro by interleukin 2.
@ast
Successful immunotherapy of na ...... ted in vitro by interleukin 2.
@en
type
label
Successful immunotherapy of na ...... ted in vitro by interleukin 2.
@ast
Successful immunotherapy of na ...... ted in vitro by interleukin 2.
@en
prefLabel
Successful immunotherapy of na ...... ted in vitro by interleukin 2.
@ast
Successful immunotherapy of na ...... ted in vitro by interleukin 2.
@en
P2860
P356
P1476
Successful immunotherapy of na ...... ted in vitro by interleukin 2.
@en
P2093
Mazumder A
Rosenberg SA
P2860
P304
P356
10.1084/JEM.159.2.495
P407
P577
1984-02-01T00:00:00Z